In Situ Hybridization (ISH) has become one of the most important molecular diagnostic technologies in modern healthcare and life sciences research. ISH techniques, including Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), are widely used for cancer diagnostics, genetic analysis, infectious disease detection, and precision medicine. The growing demand for advanced pathology solutions and companion diagnostics is driving rapid innovation in this market. Several biotechnology and diagnostics companies are leading the global ISH industry through automation, probe development, digital pathology integration, and high-sensitivity assays.
The report “In Situ Hybridization Market by Offering (Consumables, Instruments, Software), Technology (FISH (DNA FISH, RNA, PNA), CISH), Application (Cancer Diagnostics, Research, Discovery), End User (Hospitals, Pharma & Biotech, Academia) – Global Forecast to 2030 “, in situ hybridization market is expected to reach USD 2.35 billion in 2030 from USD 1.64 billion in 2025, at a CAGR of 7.4% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829
1. Roche
Roche is one of the dominant players in the ISH market through its Ventana Medical Systems division. The company offers highly automated tissue diagnostics platforms and advanced ISH assays used extensively in oncology diagnostics. Roche is especially known for companion diagnostic solutions that support targeted cancer therapies.
2. Thermo Fisher Scientific
Thermo Fisher Scientific has established a strong presence in the ISH market with a broad portfolio of probes, reagents, and pathology instruments. The company supports both clinical diagnostics and academic research laboratories worldwide. Its strong global distribution network and continuous R&D investments make it a leading ISH provider.
3. Agilent Technologies
Agilent Technologies is widely recognized for its pathology and genomic solutions. Through its Dako pathology business, the company delivers advanced ISH kits, probes, and automated staining systems. Agilent plays a major role in cancer biomarker testing and precision diagnostics.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829
4. Abbott Laboratories
Abbott Laboratories is a major force in molecular diagnostics and FISH technologies. Abbott’s extensive portfolio includes genetic testing assays and cytogenetic diagnostic products used in cancer and prenatal testing applications. The company has a strong footprint in both North America and Asia-Pacific markets.
5. Bio-Techne
Bio-Techne, through its Advanced Cell Diagnostics (ACD) division, is highly regarded for RNAscope technology. The company specializes in RNA-based ISH assays that enable highly sensitive spatial gene expression analysis. Its solutions are widely adopted in translational research and biomarker discovery.
6. Merck KGaA
Merck KGaA is another leading participant in the ISH market. Through its life science business, the company supplies high-quality reagents, probes, and genomic research solutions. Merck continues to invest heavily in molecular biology and precision medicine technologies.
7. Leica Biosystems
Leica Biosystems is known for its innovative pathology and histology solutions. The company offers automated ISH staining systems and digital pathology platforms that improve workflow efficiency in clinical laboratories. Leica Biosystems has become a preferred brand for pathology automation.
8. QIAGEN
QIAGEN provides molecular testing technologies, sample preparation solutions, and genomic analysis products. Its ISH-related offerings support infectious disease testing, oncology diagnostics, and biomarker research. The company is also expanding into companion diagnostics and personalized medicine.
9. PerkinElmer
PerkinElmer has a significant role in molecular diagnostics and imaging technologies. The company develops advanced research tools and pathology solutions that support genomic and cellular analysis. Its expertise in imaging and automation strengthens its ISH portfolio.
10. NeoGenomics Laboratories
NeoGenomics Laboratories specializes in oncology-focused diagnostic testing. The company offers FISH and molecular pathology services for cancer diagnosis and therapy selection. Its expanding laboratory network and precision oncology focus continue to drive growth in the ISH sector.
The global ISH market is expected to grow steadily due to rising cancer prevalence, increasing adoption of precision medicine, and continuous advancements in molecular pathology. Companies investing in automation, multiplex assays, spatial transcriptomics, and AI-powered pathology are expected to lead the next phase of innovation in the industry.
For more information, Inquire Now!